Posts Tagged ‘Prostate Cancer’
15 percent of cancers in men is prostate
In Europe alone there were more than 214 000 cases of prostate cancer . Statistics show that this type of cancer is the third most popular among men over 60 years. However, the prostate cancer is curable if detected early.
There are four levels of prostate cancer ranging from T1 to T4. The medical and scientific advances have helped the majority of cancers detected to be made while still in stage T1 and T2, suggesting treatment by radical prostatectomy, ie complete removal of the prostate. This form of healing has great success in patients.
However, the person may be a radical prostatectomy, the cancer must have been caught early and it is therefore recommended, and almost demanding that men over 45 years made regular prostate exams so that you can identify if there is evil.
Unfortunately, radical prostatectomy is erectile dysfunction sequel to the patient. But new technologies are allowing this complication is increasingly reduced to 10 or 15 percent of those treated.
Erectile dysfunction in prostate cancer
One of the consequences of prostate cancer is erectile dysfunction and in many cases it is a warning that something bad might be happening in the male reproductive system.
In case you did not know, there is a risk that people with prostate cancer suffering from erectile dysfunction during treatment of healing. In this way, scientists at Beth Israel Deaconess Medical Center working in conjunction with Harvard University have developed an environment that will allow them to predict what situations a man will suffer from erectile dysfunction.
No doubt one of the major concerns in most men who undergo treatment for prostate cancer is the subject of erectile dysfunction. Besides wanting to come through their illness, the other goes through a background issue that continues to be alarming to any male.
To answer such concerns, Alemozaffar Mehra is a recognized scientist who has developed a model that will reveal circumstances in which a man will suffer from erectile dysfunction. For the studies, it appears that depends on how advanced the tumor is found in the prostate, PSA levels, body mass index and age of the patient (usually young people are less likely).
Alemozaffar reached this conclusion after subjecting 1201 participants to a series of assessments of prostate cancer . Among the many research results that showed it is also known that those who have suffered from erectile dysfunction before developing prostate cancer will still face the same problem. Also, 35% of patients evaluated recognized an erection suitable for intercourse, so it was concluded that the chances of dysfunction are high.
Prostate cancer, epidemiology
Prostate cancer is the second most common cancer in Europe, after lung cancer, while in the United States has surpassed the number of cases registered and is currently the most common malignancy in men, except cancer skin. In terms of mortality ranks third after lung cancer and colorectal cancer being caused 11% of cancer deaths in men. The mortality rate in Spain is 18.1 per 100,000 inhabitants per year, meaning that approximately 7,200 people die every year from prostate cancer.
The incidence of prostate cancer has increased exponentially over the past two decades. The most likely explanation for this trend lies in changing medical surveillance. A total of 244,000 new cases are diagnosed in the United States in 1995 compared to 165,000 in 1993 and 40,400 men died from prostate cancer in 1995 compared to 35,000 deaths in 1993.
The prevalence of prostate cancer, defined as the proportion of males in the population checked clinically detectable asymptomatic cancer includes all cancers that are detectable with currently available screening methods, but does not include histological clinically detectable cancers. Thus, the true prevalence of prostate cancer is unknown, although the American Cancer Society estimated at 2.4% prevalence of prostate cancer in the asymptomatic population. 30-40% of autopsies reveal some microscopic form of prostate cancer and up to 28% of men age 50 have microscopic prostate cancer and clinically undetectable and uncertain clinical significance. That percentage rises to 83% for men over 90 years.
The natural history of prostate cancer is variable and unpredictable. There is no sufficient evidence to find out why some tumors develop metastases rapidly while others have a slower, being located throughout the patient’s life. In fact, most patients with latent prostate cancer die with cancer, rather than the disease. At present, screening for prostate cancer in asymptomatic men can not be justified as a national health policy. Could be justified only in that population goes to symptomatic prostatism visits for as long as individuals have an age below 70 years or life expectancy exceeds 10 years.
Radiation therapy and hormonal therapy in prostate cancer
It can be given external beam radiation therapy using high-energy linear accelerators or radioactive rods implanted or 198Au 125 in the prostate. The rates of impotence and urinary incontinence are somewhat lower than those that occur with surgery. Radiation therapy is the most widely used treatment for prostate carcinoma stage C.
Hormone therapy and chemical castration get a reduced androgenic stimulation of tumor. It is used as an alternative therapy for advanced-stage disease, though probably not increase survival, it does improve the quality of life for these patients. Among the options used are estrogens, LHRH analogues and antiandrogens.
The synthetic analogs of LHRH (leuprolide, buserelin, goserelin, triptorelin) act on the anterior pituitary, inhibiting the release of gonadotropins and serum testosterone levels achieved in the range of castration at 2 weeks of starting treatment. Avoid the trauma of orchiectomy and side effects of estrogen, such as gynecomastia.
Antiandrogens (cyproterone acetate, flutamide, megestrol acetate, nilumida) are competitive inhibitors of the natural receptors of androgens in target tissues, normal or malignant. Other anti-androgen drugs include finasteride, ketoconazole and suramin.
Can they find cancer in the blood?

Research conducted in the United Kingdom have drawn the attention of the American Association for Cancer Research, by making a set of biomarkers to determine whether a prostate cancer at a rate of 90% security. There is another interesting study for the organization, it is a procedure that detects blood in the majority of colon cancers when they are just beginning to take shape. It seems that in the future, breast cancer, bladder, lung, among others, could have diagnostic systems much simpler than today. Optimists believe that, even, they can replace the existing mammography, colonoscopy and biopsies.
However, so far these are only studies, pilot projects being supported by renowned experts with a solid scientific basis, but with a long distance to verify its efficiency and accuracy.
The Maitake may help fight prostate cancer and bladder
The authoritative scientific journal “British Journal of Urology” has published a new study by American scientists of the Department of Urology at New York Medical College.
In this study, the Maitake mushroom is able to reduce 75% of cancers and could pave the way for new procedures and new proposals for treatment. Read the rest of this entry »
PROSTATE: MILK AND LATICINI INCREASE THE RISK OF CANCER
Eating too often meat and dairy products may increase the risk of developing prostate cancer. This suggests a study published in the medical journal Annals of Internal Medicine which concluded that a diet rich in these foods raises levels of the hormone IGF-1 (insulin growth factor, type 1) which promotes cell growth and associated with an increased risk of developing certain cancers, including that of the prostate. Read the rest of this entry »
Walnuts are defending from prostate cancer
Nuts may help against prostate cancer by regulating the activity of genes involved, hindering the growth of the tumor (if present).
The research suggests a University of California, directed by Dr. Paul Davies and presented at the meeting in San Francisco of the American Chemical Association.
The team of Davies has worked with some rodents genetically engineered to develop prostate cancer. Read the rest of this entry »
Mistletoe for Cancer Treatment (IV)
SCIENTIFIC PUBLICATIONS
The truth is that a simple review of studies on cancer and mistletoe appeared in Publiman sample of the great interest and confirms what we have written so far. Citing only some of the studies of recent years has shown we find that response to different types of cancer.
This applies to a 2004 study on breast cancer led by Lin HS is published as Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. This is a prospective multicenter, randomized, open and conducted in three cancer centers in the People’s Republic of China: Beijing, Tianjin and Shenyang. The study was conducted along the guidelines known as Good Clinical Practice (GCP) to obtain data on the efficacy and side effects of mistletoe extract. However, “this study shows it is said in the conclusions-that the adjuvant mistletoe extract can beneficially reduce the side effects of chemotherapy in cancer patients and improve their quality of life.”
Two years later, in October 2006 – Ziegler would release another study on breast cancer entitled Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). And in that case would begin recognizing the role of mistletoe: mistletoe preparations derived as Iscador-can read it-are commonly used in the CAM / anthroposophic for many types of cancer, particularly solid cancers. Well, the study would conclude that the long-term effect on the progression of Iscador in most cases is significant, as well as on overall survival.
“Iscador-stated in the conclusions, showing a clinically relevant effect on breast tumor progression, as measured by overall survival, as well as time to recurrence, lymph node or distant metastasis. In the short term, psychosomatic self-regulation increases significantly lower complementary Iscador therapy than with conventional therapy alone.
The same researchers publish in June 2007 a new investigation, this time on cervical cancer, entitled Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). And in his return to draw conclusions that Iscador appears capable of extending overall survival, this time among patients with cervical cancer. In addition to improving quality of life. The same conclusion would later study on the effects of mistletoe in cancer of the ovary.
And they are only a few samples. Even in cancers considered very difficult to deal with encouraging results have been obtained. In 1996, for example, was published Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial of Buchler MW et al. This was a phase I / II in which we evaluated the effect of an extract of mistletoe (Eurixor) in 16 patients (7 women and 9 men) with histologically verified ductal pancreatic carcinoma. And although the results suggest that mistletoe does not have a significant influence on tumor growth in advanced pancreatic cancers do indicate that “can stabilize the quality of life and therefore help patients maintain their quality of life in the few months remaining in their life. “
We can also find good results against hepatitis C. In a 2005 study led by Dutchman Hattum J. on 21 patients with hepatitis C, the results suggested an effect comparable to treatment glicirrínico: an improvement in liver inflammation and, therefore, possible long-term reduction of complications such as cirrhosis and liver cancer. “Preparations of mistletoe-add-have the advantage of easy administration and low cost.”
THE DOCTOR’S ANGEL SPANISH EXPERIENCE Borruel
We must say, in conclusion, that during the preparation of this report we are in Internet -www.medicina-naturista.net/Congreso_Malaga_2004/Congreso_2004.htm- the paper that a Spanish doctor, Angel Borruel Omenat-member of the Spanish Association of Physicians Naturists, was introduced in Congress Naturist Medicine and Oncology in November 2004 in the Faculty of Medicine of Granada. Fortunately it was easy to locate and more talk. And that brings seventeen years Borruel using in your query Huesca mistletoe in cancer patients. As we would have had knowledge of its effectiveness through Anthroposophical Medicine-of-specialist who is also after doing a course at a clinic-the anthroposophical Lukas Arlesheim Clinik (Switzerland) – specializing in cancer where the mistletoe is fundamental treatment.
Mistletoe-start-telling “is the most widely used oncology product in Germany, including chemotherapeutic drugs of any kind, because it is perfectly compatible with any conventional treatment.
“And after 17 years of use, what can make us overall assessment of its usefulness in treating cancer?
“In cancer, the results are always the mistletoe because it strengthens the immune system and inhibits the oncogenes that stimulate angiogenesis and prevents apoptosis. At the least, improves quality of life of patients: appetite, energy and mood. In my practice of natural medicine see patients of all kinds and I would not be considered statistically valid, but in Germany, where many patients treated with mistletoe, there are studies that clearly is the increase in life expectancy. This is the case Grossarth-Maticek study done in 2002, for example, which examined 10,226 cases of patients with carcinoma of the colon, rectum, stomach, breast and lung. Of these 1668 were treated with Iscador (VAF in Spain) obtaining a longer life expectancy taxed at 40%. And when there was also a level of self-regulation in the patient is cared for, was on a diet, exercised, etc. .- the difference in expected survival reached 56%. As if today is a drug that increases life expectancy by 56% would be opening news in all news programs.
- Also affects the tumor growth mistletoe?
“It seems that in some cases and although the effect is not so much on the tumor cell as the immune system that strengthens it. The presentation of the conference held in Granada presented the case of a 17 year old girl with an astrocytoma of 3 cm with a large cerebral edema. In November 2000 he was given a life expectancy of two months. He had found two years earlier, underwent surgery and chemotherapy was administered but reappeared two years in an area where the surgery was impossible for him to be turned back to the chemo to no avail. The patient, neurologically, increasingly got worse. In November oncologists decided to suspend the chemo did not get to see any results nor gave him hope. Then started treatment with mistletoe .. but not with the VAF is marketed in Spain as in intracranial tumors can raise the blood pressure of spinal fluid. We start with a type of mistletoe called Isorel and no longer sold in Spain so we had to ask for Germany. He applied intravenously in very high doses-we put up to 20 blisters on a drip at a time-and we were changing the dose. The patient began to feel better neurologically. In spring resonance image was like in the fall but was much better neurologically. To the extent that at the end of course could participate in the concert at the conservatory. He had to give up music for their neurological problems. In the fall the tumor had already been halved and edema to a fourth or a fifth. Today the tumor is still there. Just talked to his mother last week and the oncologist had told him that the tumor was slightly better but still present. In short, we reduce the tumor and edema getting the patient to lead a completely normal life. Today is still clicking but now under the skin. Of course, other patients with astrocytoma have not been so lucky.
“Among other reasons, we assume, because when patients come to you with the disease are already at an advanced stage …
“It’s true. The vast majority get very damaged. Almost never do the first diagnosis. I already come with whatever reports were made.
“And in the cases that have come sooner, what was the outcome?
“Right now I have a patient who began treatment in early December. I was the first he saw her as a doctor. I recommended myself to go to Social Security because it had a huge tumor in her right breast but while waiting to be made all the tests I tried with mistletoe, ozone therapy at high doses, Papimi-joined this device to my office after learning to fund their chances in the last congress organized DSALUD Discovery, changed his diet, I take flax oil in large quantity and recommended antifungal therapy. The right breast tumor was reduced by 10% in little over a month and a half. Indeed, from early January to late February infiltration of the left breast tumor has completely disappeared. Just today (meaning the day we had the conversation that the reader is reading) has seen an oncologist and has said he wants to continue with the treatment of mistletoe. With the tests complete the proposed chemotherapy treatment but for now she prefers to stick with the mistletoe. We do not know where to get. One must be cautious in this. I normally try to terminally ill cancer patients with mistletoe and precancerous. Although all cases of cervical cancer that I have tried, some even in grade three, they have to negative. Always with subcutaneous injection because the oral route is much less effective. My advice also is to follow the lifelong treatment but with different dose and timing.
“What you normally do then is to complement conventional treatments …
“Yes. For example, it is common for patients who have come chemo scheduled, a drip of chemo every three weeks, but can not complete the cycle as a result of side effects, anemia, leukopenia … and thus have four weeks to distance. Then begin with the mistletoe and almost always recover the hematological level. Not until a normal level but to a level enough to get chemo every three weeks. The mistletoe is perfectly complementary with the chemo because adequate doses have no side effects.
-In your experience, is there some kind of tumor more susceptible to improvement treated with mistletoe?
“Except for lung cancer Small cell leukemia cases and all others are susceptible of improvement with the mistletoe. Both a hepatocellular adenoma and prostate cancer, an ovarian tumor as a breast or colon. In the worst response is achieved at least there is improvement in quality of life. But I never do alone. Additionally use mistletoe other therapeutic tools I mentioned before so you never know for sure what degree of improvement corresponds to each part of the treatment but I can tell you that mistletoe I put in a tumor ever. All patients with tumors that have tried for 17 years I have treated with mistletoe.
- Is also effective in the case of metastases?
“In my paper I presented another case, a woman with metastatic hypernephroma hip, lung metastases and another possible impairment. He had said only: “Go home and use pain medications as needed. When we started treatment with VAF Mali had enough pain in the hip. However, the third injection, is usually not as fast, “he began feeling better and hip pain disappeared soon after. Six months after the lung metastases had disappeared and the liver can form a tumor that was said was treatable intractable so just undergoing surgery and conventional treatment. The paradox here is that the patient ended up leaving with mistletoe treatment recommended by his oncologist.
“Being the most widely used oncology product in Germany, what attributes the ignorance that oncologists in Spain seem to have of him?
“I think that oncologists know it all but neither recommend it nor use it. Here we encountered the power of multinationals. I put my hand in the fire for the efficacy of mistletoe to improve the quality of life and survival. Sometimes even by healing the sick. But I fear that oncologists will receive information from the drug multinationals so skewed that they do not conceive it possible to achieve these results with the mistletoe. I’m not saying they have ill will. I believe as a physician that the vast majority of my colleagues want to cure their patients but clearly they are driven by information, at least, wrong. The first patient I treated was 17 years ago a young man of 30 years with adenocarcinoma of the pancreas with metastases in liver and lung. I talked to his oncologist because the family asked me and he said they were going to give palliative chemotherapy without any hope, just to see if they could prolong her life. We begin with the mistletoe and first disappeared lung and liver metastases. It was only with the primary tumor and that was removed surgically. That man is still alive. I do not know how much of his survival was the mistletoe. And I know because I was also getting chemo but given the expectations that had given it seems to me that the role of mistletoe was significant.
“Neither seem to be widely used mistletoe among naturopathic doctors …
“No, do not use it much, unfortunately. Whenever I get together with a colleague at conferences or courses will talk about the results of mistletoe in cancer because I am convinced how well it goes. At the least, improves quality of life for what the patient and patients are grateful. I think Weleda, Swiss drugmaker manufacturer does not make a good media campaign and training among doctors prone to natural medicine.
“One last question: treatment with mistletoe should always be in control of a professiona.
Prostate Cancer

It is a malignant tumor that develops in the prostate gland. It consists of uncontrolled growth of prostate cells. This means, among other things, that the prostate, because of its location, press on the bladder and urethra by preventing the normal urine output.
Most prostate cancers grow very slowly, although some do it quickly, they can even spread.
The prostate is a glandular organ, the size of a walnut, found in men and situated around the neck of the bladder and urethra, in front of the rectum. Some liquid, whitish and viscous, which is mixed with sperm at the time of ejaculation.
There are lymph vessels surrounding the prostate and that lead to pelvic lymph nodes.
When a prostate cancer, there is the possibility that cancer cells spreading through lymphatic vessels and affect the lymph and from there to anywhere on the body.
